Supernus Pharmaceuticals Inc
F:S49
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Supernus Pharmaceuticals Inc
F:S49
|
US |
|
G
|
Grandvision NV
F:8GV
|
NL |
|
T
|
TFS Financial Corp
F:PWT
|
US |
|
I
|
Interpublic Group of Companies Inc
DUS:IPG
|
US |
|
Publicis Groupe SA
F:PU41
|
FR |
|
Komercni Banka as
PSE:KOMB
|
CZ |
|
M
|
Medifast Inc
XMUN:MDF
|
US |
|
Strongpoint ASA
F:PGT
|
NO |
|
ActiveOps PLC
LSE:AOM
|
UK |
|
T
|
Talanx AG
XMUN:TLX
|
DE |
|
S
|
Salesforce Inc
DUS:FOO
|
US |
|
D
|
Danaher Corp
F:DAP
|
US |
|
C
|
CombinedX AB (publ)
STO:CX
|
SE |
|
S
|
Sealed Air Corp
F:SDA
|
US |
|
Aegon NV
F:AEND
|
NL |
|
A
|
Air Products and Chemicals Inc
XBER:AP3
|
US |
|
E
|
EDP Energias de Portugal SA
XMUN:EDP
|
PT |
|
Five Below Inc
NASDAQ:FIVE
|
US |
|
A
|
Axos Financial Inc
F:BB4
|
US |
|
A
|
Avnet Inc
F:VNI
|
US |
|
F
|
First Commonwealth Financial Corp
F:FCF
|
US |
|
NTG Nordic Transport Group AS
F:NRSA
|
DK |
|
Datatec Ltd
F:DTT
|
ZA |
|
G
|
George Weston Ltd
F:WX5
|
CA |
Wall St Price Targets
S49 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for S49 is 65.03 EUR with a low forecast of 56.57 EUR and a high forecast of 71.65 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is S49's stock price target?
Price Target
65.03
EUR
According to Wall Street analysts, the average 1-year price target for S49 is 65.03 EUR with a low forecast of 56.57 EUR and a high forecast of 71.65 EUR.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
